Currency in USDKaruna Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A.The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.Scores indicate decile rank relative to index or region. Our lead product candidate, KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s.Improving life for people living with schizophrenia, Alzheimer's disease and pain, and their families.Necessary cookies are absolutely essential for the website to function properly. 30, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website.
Karuna Therapeutics | 1,994 followers on LinkedIn | Acting compassionately to diminish the suffering of others. See insights on Karuna Therapeutics including office locations, competitors, revenue, financials, ... Karuna Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions. Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates BOSTON & PARAMUS, N.J. --(BUSINESS WIRE)--Jul. 26, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today BOSTON --(BUSINESS WIRE)--May 27, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. The company also focuses on developing other muscarinic-targeted drug candidates.
Karuna is on a Mission to develop first-in-class therapeutics that have the potential to dramatically improve life for people living with schizophrenia, Alzheimer’s disease, and pain, and their families.
BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. BOSTON --(BUSINESS WIRE)--Mar. Other executives include Stephen Brannan, Chief Medical Officer; Andrew Miller, Founder and Chief Operating Officer; and 14 others. 28, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today This category only includes cookies that ensures basic functionalities and security features of the website. Karuna Therapeutics's Chairman of the Board, President and Chief Executive Officer is Steve Paul. Improving life for people living with schizophrenia, Alzheimer's disease and pain, and their families.Our team has deep expertise in neuroscience and drug development and is committed to unlocking the potential of those living with debilitating diagnoses.We’re taking action to provide a more effective therapeutic option to the 21 million people worldwide affected by schizophrenia, as well as targeting Alzheimer’s and pain.Karuna is developing novel therapies for psychiatric and neurological disorders. About Karuna Therapeutics. You also have the option to opt-out of these cookies but opting out may have an effect on your browsing experience. See the full leadership team at Craft. By clicking “Accept”, you consent to the use of ALL the cookies. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. BOSTON --(BUSINESS WIRE)--Jul. Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia Jun 03, 2020 Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Form 4 filed by Karuna Therapeutics, Inc. with the security and exchange commission. Karuna Therapeutics has 16 employees at their 1 location. Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.Tip: Try a valid symbol or a specific company name for relevant resultsNasdaqGS - NasdaqGS Real Time Price.